TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12578106

Group type: EXPERIMENTAL
Intervention: Rocuronium administered within 1‐15 seconds
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium administered within 15‐30 seconds
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium administered within 30‐60 seconds
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rocuronium administration
Number of subjects: 60
Study: 9194141

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sulpiride (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1524684

Group type: EXPERIMENTAL
Intervention: SofScale Scaling Gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (untreated quadrants)
Number of subjects: 15
Study: 3893624

Group type: EXPERIMENTAL
Intervention: 0.3 per cent sodium hypochlorite
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 2.5 per cent povidone-iodine
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0.9 per cent saline
Number of subjects: 43
Study: 31851351

Group type: EXPERIMENTAL
Intervention: CCRT with celecoxib (200 mg twice daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: CCRT alone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CCRT with celecoxib
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CCRT with celecoxib among high-risk genotype patients
Number of subjects: 96

Group type: COMPARATOR
Intervention: CCRT alone among high-risk genotype patients
Number of subjects: 96
Study: 29967797

Group type: EXPERIMENTAL
Intervention: Unsuccessful dietary restrained group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Successful dietary restrained group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 120
Study: 26542030

Group type: EXPERIMENTAL
Intervention: Any treatment (including chemotherapy, surgery, or radiotherapy)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Local treatment (surgery and/or radiotherapy)
Number of subjects: 98

Group type: COMPARATOR
Intervention: BSC
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Local treatment
Number of subjects: 98
Study: 24131072

Group type: EXPERIMENTAL
Intervention: 1550-nm fractional laser
Number of subjects: 12

Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser (PDL)
Number of subjects: 12
Study: 22925988

Group type: EXPERIMENTAL
Intervention: S(‐)‐amlodipine nicotinate 2.5 to 5 mg once daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Amlodipine besylate 5 to 10 mg once daily
Number of subjects: 38
Study: 20174731

Group type: EXPERIMENTAL
Intervention: Transradial intervention (TRI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Transfemoral intervention (TFI)
Number of subjects: 200
Study: 18343607

Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Curriculum-and-instruction program directed at reading achievement
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard program
Number of subjects: 19
Study: 16264208

Group type: EXPERIMENTAL
Intervention: Symbiot PTFE-covered stent
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional bare-metal stent
Number of subjects: 30
Study: 12743773

Group type: EXPERIMENTAL
Intervention: Triple therapy with lansoprazole (LPZ), amoxicillin (AMPC), and clarithromycin (CAM) for 7 days
Number of subjects: 0
Study: 9578254

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 1 ml (10 mg) injected into the superior compartment of the temporomandibular joint
Number of subjects: 15
Study: 8087958

Group type: EXPERIMENTAL
Intervention: Direct thrombin inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 2753406

Group type: EXPERIMENTAL
Intervention: 10 g lactulose (L)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 g lactulose (L) with 20 mg metoclopramide (M)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 g lactulose (L)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 g lactulose (L) with 7.5 mg diphenoxylate (D)
Number of subjects: 8
Study: 795363

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 10
Study: 30376089

Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine (OPV) shedding
Number of subjects: 3
Study: 26883899

Group type: EXPERIMENTAL
Intervention: nMARQ® catheter
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single-tip ablation catheter with circular mapping catheter
Number of subjects: 35
Study: 25160673

Group type: EXPERIMENTAL
Intervention: FiO2 of 12% and 4‐hour cycling
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FiO2=21% and 4‐hour cycling
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FiO2=8.5% to 12% at rest
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FiO2=12% and 4‐hour cycling
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (normoxia)
Number of subjects: 12
Study: 23204152

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caffeine in water
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 11
Study: 20354383

Group type: EXPERIMENTAL
Intervention: Patient-centered cultural competence training
Number of subjects: 57

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 57
Study: 18599016

Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid (RA) 10 mg twice daily for eight weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no RA)
Number of subjects: 35
Study: 16000666

Group type: EXPERIMENTAL
Intervention: Metal interference screws
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bioabsorbable poly-l-lactic acid screws
Number of subjects: 41
Study: 12449148

Group type: EXPERIMENTAL
Intervention: Chemotherapy with Bonin (Disodium Pamidronate)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 34
Study: 10091407

Group type: EXPERIMENTAL
Intervention: TAL1 gene rearrangement
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity (LOH)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: TAL1 gene involvement, LOH, or MI at 1p32
Number of subjects: 17
Study: 8785026

Group type: EXPERIMENTAL
Intervention: Bright light exposure (2,000 lux) from 2.00 to 4.00 h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dark condition (resting supine in bed from 21.00 to 7.00 h)
Number of subjects: 6
Study: 2294875

Group type: EXPERIMENTAL
Intervention: Quantitative fluorometry with intravenous fluorescein administration before amputation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Clinical judgment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Quantitative fluorometry
Number of subjects: 56
Study: 76750

Group type: EXPERIMENTAL
Intervention: Simple mastectomy and postoperative radiotherapy
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Simple mastectomy alone
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Radical mastectomy alone
Number of subjects: 1020
Study: 6226527

Group type: EXPERIMENTAL
Intervention: 99mTc-DPD
Number of subjects: 257

Group type: COMPARATOR
Intervention: 99mTc-MDP 1
Number of subjects: 257

Group type: COMPARATOR
Intervention: 99mTc-MDP 2
Number of subjects: 257
Study: 31229501

Group type: EXPERIMENTAL
Intervention: BIVV009 (sutimlimab), 60 mg/kg infusions, 4 weekly doses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BIVV009 (sutimlimab)
Number of subjects: 10
Study: 28410921

Group type: EXPERIMENTAL
Intervention: MSPrebiotic®
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 26871828

Group type: EXPERIMENTAL
Intervention: Teaching assistants majored in the liberal arts (TAF)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Attending physicians (APF)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Clinical medicine-unrelated topics
Number of subjects: 123

Group type: COMPARATOR
Intervention: Clinical medicine-related topics
Number of subjects: 123
Study: 25015649

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (Se) during radiation therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 81
Study: 22549948

Group type: EXPERIMENTAL
Intervention: Caloric restriction diet (goal of 10% weight loss, N = 118)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Diet + exercise (N = 117)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Aerobic exercise (225 min/wk of moderate‐to‐vigorous activity, N = 117)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control (N = 87)
Number of subjects: 439
Study: 20809953

Group type: EXPERIMENTAL
Intervention: Home telemonitoring using the Intel Health Guide device
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (appointments as problems arise and 24-hour nurse line support)
Number of subjects: 200
Study: 17939262

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg IV q24h followed by 500 mg orally q24h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500 mg/100 mg IV q8h with oral clarithromycin 500 mg q12h, then oral amoxicillin/clavulanate 250 mg/125 mg q8h with oral clarithromycin 500 mg q12h
Number of subjects: 50
Study: 15998164

Group type: EXPERIMENTAL
Intervention: Opioid abusers
Number of subjects: 740

Group type: COMPARATOR
Intervention: Nonabusers
Number of subjects: 740
Study: 11973187

Group type: EXPERIMENTAL
Intervention: Acetaminophen 2000 mg and Celecoxib 200 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Acetaminophen 2000 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (Vitamin C, 500 mg)
Number of subjects: 112
Study: 9805728

Group type: EXPERIMENTAL
Intervention: Intervention arm (specific intervention details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (specific control details not provided)
Number of subjects: 0
Study: 7859695

Group type: EXPERIMENTAL
Intervention: Spaghetti without paracetamol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spaghetti containing 1.5 g paracetamol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mashed potatoes with 1.5 g paracetamol
Number of subjects: 8
Study: 2808056

Group type: EXPERIMENTAL
Intervention: Staging lymphadenectomy (SL)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Lymphangiography (LAG)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Both treatments (prostate vs. prostate and pelvic lymph nodes)
Number of subjects: 445
Study: 1020682

Group type: EXPERIMENTAL
Intervention: Oral dexetimide (0.5 to 1.5 mg daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no treatment with antiparkinsonian agents)
Number of subjects: 69
Study: 30663606

Group type: EXPERIMENTAL
Intervention: CVT-301 84 mg
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 27847124

Group type: EXPERIMENTAL
Intervention: Passive robotic‐assisted hand motion using the Gloreha device, twice a day for 2 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 35
Study: 25890874

Group type: EXPERIMENTAL
Intervention: Vitamins E (α‐[600 mg RRR‐α‐tocopherol, αT] and γ‐[600 mg of RRR‐γT]) and C (1000 mg ascorbic acid, AA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 24360178

Group type: EXPERIMENTAL
Intervention: Calcium Channel Blocker (CCB)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Angiotensin II Receptor Antagonist (ARB)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: CCB + ARB
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Controlled blood pressure
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Uncontrolled blood pressure
Number of subjects: 531
Study: 21900784

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg daily)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Omeprazole (20 mg daily)
Number of subjects: 542
Study: 19912686

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamivudine (LMV) 100 mg per day
Number of subjects: 0
Study: 17243057

Group type: EXPERIMENTAL
Intervention: pegylated IFN-alpha-2b (1.0 micro g/kg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: IFN-alpha-2b (3 MIU)
Number of subjects: 230
Study: 15499535

Group type: EXPERIMENTAL
Intervention: Topical GM-CSF (1-2 microg/cm2/lesion, applied 3 times weekly for 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline, applied 3 times weekly for 3 weeks)
Number of subjects: 20
Study: 10806591

Group type: EXPERIMENTAL
Intervention: 25 micrograms of triptorelin
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100 micrograms of triptorelin
Number of subjects: 30
Study: 8840994

Group type: EXPERIMENTAL
Intervention: G9-209 peptide (ITDQVPFSY)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: G9-280 peptide (YLEPGPVTA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Modified peptides (G9-209/2M and G9-280/9V)
Number of subjects: 13
Study: 1462421

Group type: EXPERIMENTAL
Intervention: Andion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Becotide
Number of subjects: 52
Study: 6152280

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg b.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 30
Study: 31416897

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 4901
Study: 28802777

Group type: EXPERIMENTAL
Intervention: LIA with liposomal bupivacaine (LB) 266 mg/20 mL (admixed with bupivacaine HCl 0.5%, 20 mL)
Number of subjects: 140

Group type: COMPARATOR
Intervention: LIA with bupivacaine HCl 0.5%, 20 mL
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: LIA with liposomal bupivacaine (LB)
Number of subjects: 140
Study: 27502855

Group type: EXPERIMENTAL
Intervention: Interactive patient support tool (active group)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Simplified tool (control group)
Number of subjects: 174
Study: 25713053

Group type: EXPERIMENTAL
Intervention: Autologous blood withdrawal (Group 1)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Autologous blood withdrawal with blood loss sequestration (Group 2)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no autologous blood withdrawal)
Number of subjects: 104
Study: 22951019

Group type: EXPERIMENTAL
Intervention: ACD/Ca(plus)/lactate
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: TSC/Ca(min)/bicarbonate
Number of subjects: 81

Group type: COMPARATOR
Intervention: Hep/lactate
Number of subjects: 81
Study: 21139879

Group type: EXPERIMENTAL
Intervention: New pictorial warnings
Number of subjects: 140

Group type: COMPARATOR
Intervention: Old text‐only warnings
Number of subjects: 140
Study: 18459999

Group type: EXPERIMENTAL
Intervention: Minimization of mycophenolate mofetil (MMF) early (30 d) after renal transplantation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Minimization of mycophenolate mofetil (MMF) late (90 d) after renal transplantation
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tacrolimus with concomitant use of diltiazem
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tacrolimus concentrations (trough > 10 ng/mL) in the first seven days after transplant
Number of subjects: 124
Study: 16905960

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 14551015

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study: 10992756

Group type: EXPERIMENTAL
Intervention: Health consultation with a practice nurse
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 132
Study: 8864793

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g, 150 ml, 15 min)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (150 ml NaCl)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L-arginine (in PPH patients)
Number of subjects: 21
Study: 1625490

Group type: COMPARATOR
Intervention: Rubidazone
Number of subjects: 611

Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Late intensification with POMP (mercaptopurine + vincristine + methotrexate + prednisone)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 611

Group type: COMPARATOR
Intervention: Prophylactic intrathecal therapy with cytosine arabinoside
Number of subjects: 611

Group type: COMPARATOR
Intervention: Maintenance with OAP (vincristine + cytosine arabinoside + prednisone)
Number of subjects: 611
Study: 6747940

Group type: EXPERIMENTAL
Intervention: Open-access physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard referral)
Number of subjects: 0
Study: 31345710

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 140
Study: 30282171

Group type: EXPERIMENTAL
Intervention: Modified cosmetic incision with intradermal suture using 6-0 absorbable Vicryl stitches and Dermabond skin adhesive
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional S shaped incision with continuous suture using 4-0 Prolene stitches
Number of subjects: 42
Study: 27012596

Group type: EXPERIMENTAL
Intervention: Rivastigmine Patch (9.5 mg/24 h)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Rivastigmine Capsule (6 mg Twice Daily)
Number of subjects: 501
Study: 25423958

Group type: EXPERIMENTAL
Intervention: Bleeper Sv radiation monitor (real-time operator dose reporting through auditory feedback)
Number of subjects: 505

Group type: COMPARATOR
Intervention: No use of Bleeper Sv radiation monitor (control group)
Number of subjects: 505
Study: 22781456

Group type: EXPERIMENTAL
Intervention: Structured triglycerides in Group A (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: MCT/LCT in Group B (n = 10)
Number of subjects: 20
Study: 19732126

Group type: EXPERIMENTAL
Intervention: Glutamine (Dipeptiven, Fresenius) as continuous infusion for 6 hours at 0.5 g/kg for 3 days prior to, and 7 days following surgery
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Glutamine (Dipeptiven, Fresenius)
Number of subjects: 55
Study: 18729297

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention, n = 15, received 9 bi-weekly 1-hour individual sessions.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control condition, n = 12.
Number of subjects: 27
Study: 15937879

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied during maximal voluntary contraction (MVC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) applied during muscle relaxation (control experiment)
Number of subjects: 10
Study: 12598273

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (5 and 10 microg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (2.5 and 5 microg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2% hyperbaric mepivacaine alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2% hyperbaric mepivacaine combined with intrathecal opioids
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study: 10232431

Group type: EXPERIMENTAL
Intervention: Surgically treated pulmonary stenosis (PS) children at rest
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Surgically treated pulmonary stenosis (PS) children during exercise
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control children during exercise
Number of subjects: 117
Study: 8290676

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (FZD)
Number of subjects: 208
Study: 3825935

Group type: EXPERIMENTAL
Intervention: 50 mg slow-release IS-5MN
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 100 mg slow-release IS-5MN
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 28857848

Group type: COMPARATOR
Intervention: IV amikacin 20 mg/kg once daily
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Nebulized amikacin 400 mg twice daily
Number of subjects: 133
Study: 27412108

Group type: EXPERIMENTAL
Intervention: Intravenous methylnaltrexone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 25880761

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) transfusion (12 ml/kg)
Number of subjects: 33
Study: 23469933

Group type: EXPERIMENTAL
Intervention: Bipolar plasma enucleation of the prostate (BPEP)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 140
Study: 21613358

Group type: EXPERIMENTAL
Intervention: 72‐h fasting
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1‐h exercise (65% VO(2max))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Basal state
Number of subjects: 8
Study: 19100647

Group type: EXPERIMENTAL
Intervention: Irinotecan/gemcitabine (IG) regimen (gemcitabine 1000mg/m² i.v. on days 1 and 8 and irinotecan 300mg/m² i.v. on day 8) every 3 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Irinotecan (I) monotherapy (300mg/m² i.v. on day 1) every 3 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Irinotecan/gemcitabine (IG) regimen
Number of subjects: 69

Group type: COMPARATOR
Intervention: Irinotecan (I) monotherapy
Number of subjects: 69
Study: 16720794

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15304299

Group type: EXPERIMENTAL
Intervention: Prototype sports drink containing calcium and maltodextrin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Drink with calcium (positive control)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 18
Study: 11765070

Group type: EXPERIMENTAL
Intervention: Opioids (morphine)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TC)
Number of subjects: 43